<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03818919</url>
  </required_header>
  <id_info>
    <org_study_id>123191</org_study_id>
    <nct_id>NCT03818919</nct_id>
  </id_info>
  <brief_title>Nonopioid Analgesia After Rotator Cuff Repair</brief_title>
  <official_title>Traditional vs. Nonopioid Analgesia After Rotator Cuff Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, single blinded, standard of care controlled clinical trial. This
      project aims to compare postoperative pain control in patients in two treatment arms of
      rotator cuff repair: a treatment group given a nonopioid pain control regimen, and a standard
      of care control group given standard opioid pain control regimen
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: This is a randomized, single blinded, standard of care-controlled clinical
      trial. All adult patients over eighteen desiring rotator cuff repair will be eligible.
      Nonnarcotic postoperative pain control regimen described below were chosen based on previous
      studies in fracture care and joint arthroplasty.

      Patients will be consented and recruited. Once participation has been determined and consent
      obtained, the names of participating patients will be provided to the research pharmacy.
      Patients will be randomized with a computer-generated table in 2 patient blocks by the
      research pharmacy. Patients postoperative analgesia will be divided into one of the following
      2 treatment arms: 1) A novel nonopioid pain protocol or 2) traditional narcotic pain
      analgesia

      Primary endpoints is reduction in pain as measured by visual analogue scale and
      Patient-Reported Outcomes Measurement Information System. The endpoints will be collected at
      each post-operative day using a journal. Moreover, endpoints will be collected at the
      patient's first post-operative appointment. These appointments are scheduled within one-week
      of the index procedure.

      Statistical Analysis: All continuous data will be analyzed using independent 2-group t tests
      and reported as means Â± standard deviations. Categorical data will be compared between the 2
      groups using chi-square tests and reported as counts and percentages. A preliminary test to
      confirm the quality of variances will be conducted prior to utilizing the t test to confirm
      the appropriate statistical analysis. Nonparametric equivalents Wilcoxon rank-sum and Fisher
      exact tests will be used as needed for nonnormal distributions and low variable numbers,
      respectively. A multivariable regression analysis was performed to assess for potential
      confounding demographic variables.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2019</start_date>
  <completion_date type="Anticipated">May 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Levels</measure>
    <time_frame>10 days post-operatively</time_frame>
    <description>Patients record pain levels every 3 hours using Visual analog scales for 10 days post-operatively. Average daily pain was calculated for each patient. Higher values portend worse control.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-Reported Outcomes Measurement Information System</measure>
    <time_frame>10 days post-operatively</time_frame>
    <description>Patient-Reported Outcomes Measurement Information System Physical Interference (PROMIS PI) once every night for 10 days post-operatively. Average PROMIS PI values calculated nightly. A higher score indicates more pain interference.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Rotator Cuff Tear</condition>
  <arm_group>
    <arm_group_label>Post-Operative Non Opioid Pain Protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will be administered a novel multimodal pain protocol post-operatively consisting of: Celecoxib, Ketorolac, Gabapentin, Acetaminophen, Diazepam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-Operative Traditional Pain Protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be administered a traditional post-operative pain protocol consisting of: Hydrocodone-Acetaminophen Cap 5-500</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Post-Operative Non Opioid Pain Protocol</description>
    <arm_group_label>Post-Operative Non Opioid Pain Protocol</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>Post-Operative Non Opioid Pain Protocol</description>
    <arm_group_label>Post-Operative Non Opioid Pain Protocol</arm_group_label>
    <other_name>Tylenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>Post-Operative Non Opioid Pain Protocol</description>
    <arm_group_label>Post-Operative Non Opioid Pain Protocol</arm_group_label>
    <other_name>Neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>Post-Operative Non Opioid Pain Protocol</description>
    <arm_group_label>Post-Operative Non Opioid Pain Protocol</arm_group_label>
    <other_name>Tylenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diazepam</intervention_name>
    <description>Post-Operative Non Opioid Pain Protocol</description>
    <arm_group_label>Post-Operative Non Opioid Pain Protocol</arm_group_label>
    <other_name>Valium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocodone-Acetaminophen</intervention_name>
    <description>Traditionally used narcotic pain protocol</description>
    <arm_group_label>Post-Operative Traditional Pain Protocol</arm_group_label>
    <other_name>Norco</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult patients over age 18 and scheduled for a primary or revision rotator cuff
             repair

        Exclusion Criteria:

          -  Exclusion criteria will include patients with a medical history of known allergies or
             intolerance to allergies or intolerance to Celebrex, Tylenol, Neurontin,
             dexamethasone, tramadol, substantial alcohol or drug abuse, and pregnancy, history of
             narcotics within 6 months of surgery, renal impairment, peptic ulcer disease, GI
             bleeding. Secondary exclusion criterion is an intact rotator cuff
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toufic R Jildeh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Resident</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toufic R Jildeh, MD</last_name>
    <phone>5172308511</phone>
    <email>tjildeh1@hfhs.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Health Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toufic R Jildeh, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 22, 2019</study_first_submitted>
  <study_first_submitted_qc>January 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2019</study_first_posted>
  <last_update_submitted>January 24, 2019</last_update_submitted>
  <last_update_submitted_qc>January 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Toufic R. Jildeh</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rotator Cuff Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Acetaminophen, hydrocodone drug combination</mesh_term>
    <mesh_term>Diazepam</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Hydrocodone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Per Request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

